|Day Low/High||86.71 / 87.00|
|52 Wk Low/High||74.97 / 96.31|
Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.
Novartis shares led gainers in Zurich Tuesday after the pharmaceuticals group held on to full year earnings targets and narrowly beast analysts' forecasts for first quarter earnings.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Earnings and hopes for a tax plan help lift the markets. Portfolio moves include exiting a utility position.
The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite Pharma's competing "CAR-T" KTE-C19 in the same DLBCL patients.
The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite's competing 'CAR-T' KTE-C19 in the same DLBCL patients.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The maker of the EpiPen seems incapable of overcoming its troubles.
The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
Novartis shares fell after it said a potentially key cardiovascular treatment had failed a global clinical trial, putting doubt over the group's ability to offset slowing heart disease drug sales.
The Democrats aim to generate public opposition to repeal by offering amendments that highlight fears the GOP plan will result in more expensive insurance and fewer people with coverage.
Stocks fall for a second day on Tuesday, the first back-to-back decline since January, as a selloff in health care spoils attempts by the market to push higher.
Stocks slump Tuesday as a selloff in health care spoils an attempt by the market to push higher.
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
Stocks are in flux on Tuesday as Donald Trump makes vague promises to lower drug prices, while Republicans unveil their bill to tackle health care reform.
European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.
President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.
Novartis shares fell in Zurich Thursday after it had the sales of some of its drugs banned in South Korea following a fine from food and drug safety officials.
Kite intends to submit a marketing application for KTE-C19 to the U.S. Food and Drug Administration by the end of March.
Norway's sovereign wealth fund, the world's biggest and a key investor in Apple and Alphabet, earned more than $53 billion last year as equity returns surged.
Novartis has seen some very aggressive buying the past five months -- time to join in.
Numerous studies show that corporate carve outs deliver robust returns.
The drug company will carry out 80% of a $2B repurchase by Feb. 28 after pressure from insurgent Jana Partners. Icahn also reportedly acquired a stake, with focus on M&A.
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
Cellectis is taking another step to move immunotherapy 'off the shelf.'
The pharmaceutical company has signed a deal to sell its intrathecal therapy segment to a Piramal Enterprises subsidiary for up to $203 million.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.